ArticleThe oncologist2016
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies.Frontiers in pharmacology · 2023Pooled it
- Management of liver metastases from uveal melanoma.The British journal of surgery · 2025Review
- PDGFR-α shRNA-polyplex for uveal melanoma treatment via EMT mediated vasculogenic mimicry interfering.Journal of nanobiotechnology · 2024Article
- Current trends in the characterization and monitoring of vascular response to cancer therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Plaque Radiotherapy for Ocular Melanoma.Cancers · 2024Review
- Identification and validation of a costimulatory molecule-related signature to predict the prognosis for uveal melanoma patients.Scientific reports · 2024Article
- Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients.Cancers · 2023Article
- Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.Therapeutic advances in medical oncology · 2023Review
- Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Uveal Melanoma Metastasis.Cancers · 2021Review
- Molecular Markers and Targets in Melanoma.Cells · 2021Review
- Article
- Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors.Current oncology reports · 2021Review
- Review
- Hypoxia-dependent drivers of melanoma progression.Journal of experimental & clinical cancer research : CR · 2021Review
- Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma.Life (Basel, Switzerland) · 2020Article
- Review
- Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents.Journal of clinical medicine · 2020Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn experimental models, bevacizumab suppressed in vitro growth and in vivo hepatic metastasis of ocular melanoma cells. Additional preclinical data suggested a potential benefit when combining bevacizumab with dacarbazine.
methodsThis noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m(2) on days 1-7 and 15-21) in 36 patients with metastatic uveal melanoma (MUM). The primary endpoint was the progression-free rate (PFR) at 6 months. Using a modified 2-step Fleming plan, at least 10 of 35 patients were required to support a predefined PFR at 6 months of 40%. Secondary objectives were progression-free survival (PFS), overall survival (OS), and safety; liver perfusion computed tomography (CT) for response imaging; and impact of VEGF-A gene polymorphisms on bevacizumab pharmacodynamics.
resultsFirst- and second-step analyses revealed nonprogression at 6 months in 3 of 17 and 8 of 35 patients, respectively. Finally, the 6-month PFR was 23% (95% confidence interval [CI]: 10-39), with long-lasting stable disease in 5 patients (14%). Median PFS and OS were 12 weeks and 10 months, respectively. No unexpected toxicity occurred. Liver perfusion CT imaging was not useful in assessing tumor response, and VEGF-A gene polymorphisms were not correlated with toxicity or survival.
conclusionIn patients with MUM, a combination of bevacizumab plus temozolomide achieved a 6-month PFR of 23%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.